Antioxidants and Proinflamatory Cytokines in the Sera of Patients with Cutaneous Leishmaniasis

Authors

  • Ali Khamesipour Leprosy and Dermal Disease Center, Tehran University of Medical Sciences
  • Nematollah Khansari Department of Immunology, Faculty of Medicine
  • Saied Bokaie Department of Pathobiology, Veterinary Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abstract:

Background: Leishmania is a significant health problem in many parts of the world. Tumor necrosis factor (TNF) plays an essential role in Leishmania major infections. Objective: To study the pro-inflammatory cytokines and antioxidants in four groups of cutaneous leishmaniasis patients. Methods: 39 patients were divided into four groups of: 1) active (acute phase of treatment); 2) non-healing (received treatment for almost two years without recovery); 3) healing (recovered upon treatment); and 4) healed (previously received treatment and achieved complete remission) patients. Serum levels of pro-inflammatory cytokines (IL-1B, TNF-α, IL-6) and serum antioxidant levels were measured by ELISA and FRAP assays, respectively. Results: While serum antioxidant levels were elevated in the non-healing group, there was no difference among other groups of patients and healthy controls in this regard. Interleukin-1β showed the highest level in the non-healing group followed by the other groups of patients. The mean serum IL-6 level was highest in the non-healing group, but showed no significant change in the other groups. TNF-α and IL-1β levels were non-significantly elevated in the sera of active and non-healing patients. Conclusion: Pro-inflammatory cytokines IL-1β, TNF-α, IL-6 maybe related to the progression of leishmaniasis. Serum antioxidant levels maybe correlated with patient response to drug treatment.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

antioxidants and proinflamatory cytokines in the sera of patients with cutaneous leishmaniasis

background: leishmania is a significant health problem in many parts of the world. tumor necrosis factor (tnf) plays an essential role in leishmania major infections. objective: to study the pro-inflammatory cytokines and antioxidants in four groups of cutaneous leishmaniasis patients. methods: 39 patients were divided into four groups of: 1) active (acute phase of treatment); 2) non-healing (r...

full text

Quality of life in patients with cutaneous leishmaniasis

Introduction: Cutaneous Leishmaniasis (CL) is characterized by papules, nodules or ulcers that most often leave permanent scars in exposed areas of body. This condition can have a severe effect on the quality of life in these patients. This study aims to examine the quality of life in patients with CL. Methods: This cross-sectional study evaluated 120 patients (52 males and 67 females) betwe...

full text

Adenosine deaminase activities in sera, lymphocytes and granulocytes in patients with cutaneous leishmaniasis.

Adenosine deaminase (ADA) activities in sera, lymphocytes and granulocytes in patients with cutaneous leishmaniasis were investigated and compared with control groups. Fifty patients and 50 healthy individuals were studied. The clinical diagnosis was parasitologically confirmed by culture and Giemsa stain. ADA activities were measured by colorimetric method. Serum ADA activities 37.80 +/- 11.90...

full text

Antimonial treatment failure rate in patients with cutaneous leishmaniasis

Background: Despite advances in diagnosis and treatment, leishmaniasis is now considered a severe public health problem, particularly in developing countries, such as Iran. Leishmaniasis is among the six most important, parasitic diseases of the world affecting 88 countries in almost every continent. The disease is complex with different clinical presentations such as visceral, cutaneous and mu...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 9  issue 3

pages  208- 214

publication date 2012-09-01

By following a journal you will be notified via email when a new issue of this journal is published.

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023